Skip to content
DraconiticResearch
Search Sources API
190,869 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY 4.0Journal of Cancer Research and Clinical Oncology

Intensity-modulated radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy for locoregional recurrent cervical cancer: a single-institutional phase II investigator-initiated nonrandomized clinical trial

  • Chi Fang1,2
  • Suping Liu1,2
  • Jie Xia3
  • Xiaohua Wu1,2
  • Guihao Ke1,2
  • Jun Zhu1,2
  1. 1Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032 China
  2. 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
  3. 3Department of Digestive Endoscopic Center, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Read full textDOICite

Abstract

Objective: To prospectively explore efficacy and safety of radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy for locoregional recurrent cervical cancer (CC).

Methods: Patients with locoregional recurrent CC were enrolled in the analysis. The enrolled patients received radiotherapy and albumin-bound paclitaxel and platinum-based chemotherapy. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate (ORR), and safety.

Results: 99 patients were enrolled. For all patients, the 3-year PFS and 3-year OS were 48.5% and 58.6%. 17.2% of patients achieved CR and 67.7% of patients achieved PR. The ORR was 84.8%. Moreover, 10.1% of patients were confirmed SD. The DCR was 94.9%.

Conclusion: Locoregional recurrent CC could benefit from radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy.

Related

  1. Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma : A Phase 2 Nonrandomized Clinical Trial
    Raquibul Hannan, Lin Lin, Ryan Assadi +13
    JAMA oncologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Evaluation of clinical outcomes and prognostic factors in patients with metastatic appendiceal adenocarcinoma treated with first-line chemotherapy: A multi-institutional retrospective study
    Koshiro Fukuda, Hiroki Osumi, Atsuo Takashima +15
    Therapeutic Advances in Medical OncologyPeer-reviewedCC BYFull textSurgery & anaesthesiaDOAJ
  3. PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis
    Samuel M. Vorbach, Thomas Seppi, Giulia Santo +11
    European Journal of Nuclear Medicine and Molecular ImagingPeer-reviewedCC BY 4.0Full textMedical imaging & radiologyPMC
  4. CYLD: A Key Factor and Novel Predictive Biomarker of Cross-Resistance to Chemotherapy and Radiotherapy in Oral Squamous Cell Carcinoma.
    Kou Yonemaru, Naoki Suenaga, Takeshi Masuda +9
    International journal of biological sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research
    Yan Xu, Hui Guan, Yuan Wu +4
    Journal of translational internal medicinePeer-reviewedCC BYFull textOncologyEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{fang2026intensitymodulated,
  title = {{Intensity-modulated radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy for locoregional recurrent cervical cancer: a single-institutional phase II investigator-initiated nonrandomized clinical trial}},
  author = {Chi Fang and Suping Liu and Jie Xia and Xiaohua Wu and Guihao Ke and Jun Zhu},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2026},
  month = jul,
  doi = {10.1007/s00432-026-06555-0},
  url = {https://doi.org/10.1007/s00432-026-06555-0},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Intensity-modulated radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy for locoregional recurrent cervical cancer: a single-institutional phase II investigator-initiated nonrandomized clinical trial
AU  - Chi Fang
AU  - Suping Liu
AU  - Jie Xia
AU  - Xiaohua Wu
AU  - Guihao Ke
AU  - Jun Zhu
PY  - 2026
DA  - 2026/07/28
JO  - Journal of Cancer Research and Clinical Oncology
DO  - 10.1007/s00432-026-06555-0
UR  - https://doi.org/10.1007/s00432-026-06555-0
AB  - Objective: To prospectively explore efficacy and safety of radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy for locoregional recurrent cervical cancer (CC).  Methods: Patients with locoregional recurrent CC were enrolled in the analysis. The enrolled patients received radiotherapy and albumin-bound paclitaxel and platinum-based chemotherapy. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate (ORR), and safety.  Results: 99 patients were enrolled. For all patients, the 3-year PFS and 3-year OS were 48.5% and 58.6%. 17.2% of patients achieved CR and 67.7% of patients achieved PR. The ORR was 84.8%. Moreover, 10.1% of patients were confirmed SD. The DCR was 94.9%.  Conclusion: Locoregional recurrent CC could benefit from radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy.
SN  - 0171-5216
SN  - 1432-1335
ER  -